• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by GoodRx Holdings Inc.

    6/11/24 7:01:15 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    SC 13D/A 1 gdrx-trevorbezdekschedule1.htm SC 13D/A GDRX - Trevor Bezdek Schedule 13D (Amendment No. 2)
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D/A
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    GoodRx Holdings, Inc.
    (Name of Issuer)
    Class A Common Stock
    (Title of Class of Securities)
    38246G108
    (CUSIP Number)
    Trevor Bezdek
    c/o GoodRx Holdings, Inc.
    2701 Olympic Boulevard
    Santa Monica, CA 90404
    (855) 268-2822
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
    June 7, 2024
    (Date of Event Which Requires Filing of This Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject
    of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the
    following box. [ ]
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including
    all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
    _____________
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with
    respect to the subject class of securities, and for any subsequent amendment containing information which would
    alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose
    of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of
    the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    1
    Names of Reporting Persons
    Trevor Bezdek
    2
    Check the Appropriate Box if a Member of a Group                                    (a) [ ]
                                                                                                                (b) [ ]
    3
    SEC Use Only
    4
    Source of Funds (See Instructions)
    OO
    5
    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ]
    6
    Citizenship or Place of Organization
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH
    7
    Sole Voting Power
    2,632,721
    8
    Shared Voting Power
    2,632,721
    9
    Sole Dispositive Power
    2,632,721
    10
    Shared Dispositive Power
    2,632,721
    11
    Aggregate Amount Beneficially Owned by Each Reporting Person
    5,265,442
    12
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ]
    13
    Percent of Class Represented by Amount in Row (11)
    5.6%
    14
    Type of Reporting Person
    IN
    CUSIP No. 38246G108
    13D/A
    Page 1 of 6 pages
    EXPLANATORY NOTE
    This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) amends and
    supplements the statement on Schedule 13D filed with the Securities and Exchange Commission
    on August 31, 2023 (as amended to date, the “Schedule 13D”) relating to the shares of Class A
    Common Stock, par value $0.0001 per share (the “Class A Common Stock”), of GoodRx
    Holdings, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used but not defined
    herein shall have the meaning ascribed thereto in the Schedule 13D.
    Item 4.Purpose of Transaction.
    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
    Gift Transactions
    On June 7, 2024, the Reporting Person gifted 2,632,721 shares of Class A Common
    Stock to the Reporting Person’s spouse.
    On June 10, 2024, the Reporting Person gifted 2,632,721 shares of Class A Common
    Stock to a grantor retained annuity trust (the “TB 2024 GRAT”) of which the Reporting Person
    is the sole trustee and annuitant. Also on June 10, 2024, the Reporting Person’s spouse gifted
    2,632,721 shares of Class A Common Stock to a grantor retained annuity trust (the “JB 2024
    GRAT”), of which the Reporting Person’s spouse is the sole trustee and annuitant.
    As a result of the foregoing transactions, the Reporting Person no longer has voting or
    dispositive power over the Class A Common Stock held by the JB 2024 GRAT. The Reporting
    Person does not exercise voting or dispositive power over the Class A Common Stock held of
    record by the JB 2024 GRAT. The inclusion in this Amendment No. 2 of the Class A Common
    Stock held of record by the JB 2024 GRAT and disclosure related thereto is not an admission or
    acknowledgement that the Reporting Person beneficially owns such Class A Common Stock.
    The Reporting Person disclaims beneficial ownership of the Class A Common Stock held by the
    JB 2024 GRAT.
    Rule 10b5-1 Trading Plans
    On June 7, 2024, pursuant to the Board’s prior approval in accordance with the terms of
    the Reporting Person’s Second Amended and Restated Employment Agreement, the Reporting
    Person terminated the Trading Plan and entered into a modified Rule 10b5-1 Plan (the “TB 2024
    GRAT Trading Plan”), pursuant to which the Reporting Person and the TB 2024 GRAT may
    make periodic sales of up to 2,632,721 shares of Class A Common Stock plus an undeterminable
    number of Class A Common Stock related to restricted stock units that have not yet vested. The
    amount and timing of sales, if any, pursuant to the TB 2024 GRAT Trading Plan may vary and
    CUSIP No. 38246G108
    13D/A
    Page 2 of 6 pages
    will be determined based on the terms of the TB 2024 GRAT Trading Plan, market conditions,
    share price and other factors.
    Also on June 7, 2024 and further pursuant to the Board’s prior approval in accordance
    with the terms of the Reporting Person’s Second Amended and Restated Employment
    Agreement, the Reporting Person’s spouse entered into a new Rule 10b5-1 Plan (the “JB 2024
    GRAT Trading Plan”), pursuant to which the JB 2024 GRAT may make periodic sales of up to
    2,632,721 shares of Class A Common Stock. The amount and timing of sales, if any, pursuant to
    the JB 2024 GRAT Trading Plan may vary and will be determined based on the terms of the JB
    2024 GRAT Trading Plan, market conditions, share price and other factors.
    The foregoing descriptions of the TB 2024 GRAT Trading Plan and the JB 2024 GRAT
    Trading Plan do not purport to be complete and are qualified in their entirety by the full text of
    such trading plans. A copy of each of the TB 2024 GRAT Trading Plan and the JB 2024 GRAT
    Trading Plan is filed as an exhibit to this Schedule 13D, and incorporated herein by reference.
    Item 5.Interest in Securities of the Issuer.
    Item 5 of the Schedule 13D is hereby amended and restated as follows:
    (a) – (b)
    •Amount beneficially owned: 5,265,442†
    •Percent of Class: 5.6%†
    •Number of shares the Reporting Person has:
    oSole power to vote or direct the vote: 2,632,721
    oShared power to vote: 2,632,721†
    oSole power to dispose or direct the disposition of: 2,632,721
    oShared power to dispose or direct the disposition of: 2,632,721†
    The share amount reported herein consists of (i) 2,632,721 shares of Class A Common
    Stock held by the TB 2024 GRAT and (ii) 2,632,721 shares of Class A Common Stock held by
    the JB 2024 GRAT.†
    The above percentage is based on 94,335,792 shares of Class A Common Stock
    outstanding as of April 30, 2024, as disclosed in the Quarterly Report of the Issuer on Form 10-Q
    filed with the Securities and Exchange Commission on May 9, 2024.
    CUSIP No. 38246G108
    13D/A
    Page 3 of 6 pages
    † The Reporting Person does not exercise voting or dispositive power over the Class A Common
    Stock held of record by the JB 2024 GRAT. The inclusion in this Amendment No. 2 of the Class
    A Common Stock held of record by the JB 2024 GRAT and disclosure related thereto is not an
    admission or acknowledgement that the Reporting Person beneficially owns such Class A
    Common Stock. The Reporting Person disclaims beneficial ownership of the Class A Common
    Stock held by the JB 2024 GRAT.
    (c)On June 1, 2024, the Reporting Person acquired 126,552 shares of Class A Common
    Stock as a result of the vesting of RSUs, after the Issuer withheld 130,042 shares of Class
    A Common Stock underlying Class B Common Stock from the Reporting Person to
    satisfy tax withholding obligations. Except as described in this Amendment No. 2, in the
    last 60 days, the Reporting Person has not effected any transactions with respect to the
    Class A Common Stock.
    (d)None.
    (e)Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to
    Securities of the Issuer.
    Item 6 of the Schedule 13D is hereby amended and supplemented as follows:
    Item 4 above summarizes certain provisions of the TB 2024 GRAT Trading Plan and the
    JB 2024 GRAT Trading Plan and is incorporated herein by reference. A copy of each of the TB
    2024 GRAT Trading Plan and the JB 2024 GRAT Trading Plan is attached as an exhibit to this
    Schedule 13D, and incorporated herein by reference.
    Item 7.Materials to be Filed as Exhibits.
    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:
    Exhibit
    Number
    Description
    5
    TB 2024 GRAT Trading Plan.
    7
    JB 2024 GRAT Trading Plan.
    CUSIP No. 38246G108
    13D/A
    Page 4 of 6 pages
    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the
    information set forth in this statement is true, complete and correct.
    Date:  June 11, 2024
    By:
    /s/ Trevor Bezdek
    Name:
    Trevor Bezdek
    CUSIP No. 38246G108
    13D/A
    Page 5 of 6 pages
    Get the next $GDRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    Mizuho initiated coverage on GoodRx with a new price target

    Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

    12/4/24 7:38:07 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by Raymond James with a new price target

    Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

    8/9/24 7:30:17 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Director Rey-Giraud Agnes gifted 75,219 shares and received a gift of 75,219 shares, decreasing direct ownership by 47% to 85,448 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/19/25 6:07:00 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin covered exercise/tax liability with 1,719 shares and converted options into 4,804 shares, increasing direct ownership by 2% to 137,292 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/15/25 6:36:46 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 6% to 134,207 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/8/25 5:15:01 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

    Until today, Ozempic® has not been available to eligible self-paying patients at this price GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic® has been made available to patients at this self-pay price.

    8/18/25 9:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:20:51 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:12:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by GoodRx Holdings Inc.

    SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    7/3/25 7:23:11 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve

    7/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports First Quarter 2025 Results

    First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

    5/7/25 4:13:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology